SUBSCRIBE
SUBSCRIBE
Mollie Barnes

Mollie Barnes

Freelance writer

Mollie Barnes is a freelance science writer. Reach her at mollie@100yearsco.com. Follow her on Threads and Instagram @shejustlikedtogo or LinkedIn. See more of her work at molliebarnes.contently.com.

D2C Direct to Consumer, eCommerce strategy aimed directly at consumer, Virtual Screen Technology
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
 · 
5 min read
 · 
Mollie Barnes
exteriors of Merck, Biogen and BMS
Deals
Top I&I Deals So Far in 2024
The size of the global immunology market is projected to nearly double by 2032 to a quarter of a trillion dollars. Here are this year’s standout deals in the space.
August 7, 2024
 · 
5 min read
 · 
Mollie Barnes
Deals
Companies to Watch for Potential M&As in 2024
Analysts predict a booming year for mergers and acquisitions, powered by obesity drug sales and pressure from upcoming patent expirations.
June 4, 2024
 · 
4 min read
 · 
Mollie Barnes
Drug Development
ASCO24 Preview: A Look at Some of the Cancer Meeting’s Hottest Abstracts
The American Society of Clinical Oncology annual meeting kicks off today in Chicago, with highly anticipated presentations that include reports on a bispecific antibody, an ADC and a BCMA-targeted CAR-T cell therapy.
May 30, 2024
 · 
3 min read
 · 
Mollie Barnes
Pictured: An antibody-drug conjugate under construction by two scientists/ Nicole Bean for BioSpace
Drug Development
Despite Progress, ADCs Still Stalled in Non-Small Cell Lung Cancer
Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients with lung cancer, experts told BioSpace.
May 20, 2024
 · 
5 min read
 · 
Mollie Barnes
Pictured: Abstract viruses and DNA
Drug Development
AAVs in Focus at ASGCT: Improved Precision, Targeting Common Diseases
Adeno-associated viruses have long been go-to vectors for gene therapies. How AAVs are improving will be among the cell and gene therapy topics to be covered in Baltimore this week.
May 3, 2024
 · 
4 min read
 · 
Mollie Barnes
Pictured: AbbVie building and needle/Taylor Tieden
Policy
Biosimilar Sales Up as Insurers Begin Dropping Humira Coverage
Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.
April 22, 2024
 · 
4 min read
 · 
Mollie Barnes
Pictured: Contract work collage/Taylor Tieden for
Career Advice
Recently Laid Off? Contract Work Could Be an Attractive Option
Staffing agencies say contract work is a great way to break into an industry and avoid a resume gap.
March 13, 2024
 · 
4 min read
 · 
Mollie Barnes
Pictured: An illustration of a semi-truck hauling
Drug Development
Analysts Predict Slower Rollout but Ultimate Victory for Casgevy in Race with Lyfgenia
Vertex and CRISPR Therapeutics are setting up treatment centers for patients with beta thalassemia and sickle cell disease to compete with bluebird’s established infrastructure.
March 12, 2024
 · 
5 min read
 · 
Mollie Barnes
Pictured: Baisong Mei/Nicole Bean for BioSpace
Business
Baisong Mei’s Immigrant Journey Through American Biopharma
From entering college in China at just 15 to co-inventing a drug for Bayer, Mei’s career journey has been far from average. Now CMO at Editas, he’s not done yet.
February 27, 2024
 · 
4 min read
 · 
Mollie Barnes
Business
How a Promise Sparked Ray CEO Paul Bresge’s Quest to Treat a Blinding Disease
After Tamar Bresge was diagnosed with retinitis pigmentosa at age 15, her entrepreneurial father made it his mission to help find a cure.
January 30, 2024
 · 
4 min read
 · 
Mollie Barnes
Pictured: Overlaid photographs of buildings, stock
Despite Tough Market, Some Life Science IPOs Find Success
The handful of biotechs that went public in 2023 fared well, providing hope to a cautiously optimistic sector.
January 16, 2024
 · 
4 min read
 · 
Mollie Barnes
Pictured: Hannah Wastyk/Background by Nicole Bean
Business
Hannah Wastyk’s Path from Academia to Biotech
The Interface Biosciences co-founder said forging the relationships needed to launch a startup can be a challenge for members of underrepresented groups, making confidence and adaptability key.
January 3, 2024
 · 
5 min read
 · 
Mollie Barnes
Pictured: A hand holding a stick with a carrot tie
Business
Does Pay for Performance Work? It Depends
A study finds that employees are more likely to view pay for performance positively—and rise to the challenge of performing well—when they view their managers as friendly and good at their jobs.
December 20, 2023
 · 
6 min read
 · 
Mollie Barnes
Arrows lead to a graph of a downward trend, then c
How to Cope with Layoffs and Other Career Setbacks
Being laid off, experiencing a trial failure or failing to secure funding can feel crushing. Here’s how to maintain perspective and move on.
December 13, 2023
 · 
4 min read
 · 
Mollie Barnes
Load More